Halozyme Therapeutics (HALO) Total Debt (2013 - 2026)

Halozyme Therapeutics (HALO) has 14 years of Total Debt data on file, last reported at $2.1 billion in Q1 2026.

• Total Debt for Q1 2026 came in at $2.1 billion, up 42.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.1 billion (up 42.27% YoY), and the FY2025 annual result was $2.1 billion, up 42.29% from the prior year.
• Total Debt steadied at $2.1 billion in Q1 2026 per HALO's latest filing, from $2.1 billion in the prior quarter.
• Over five years, Total Debt peaked at $2.1 billion in Q1 2026 and troughed at $89.5 million in Q1 2022.
• A 5-year average of $1.4 billion and a median of $1.5 billion in 2024 frame the typical range for Total Debt.
• The sharpest annual moves came in 2022 and 2023: Total Debt jumped 1585.66% in 2022, then declined 0.46% in 2023.
• A 5-year view of Total Debt shows it stood at $1.5 billion in 2022, then retreated by 0.45% to $1.5 billion in 2023, then grew by 0.44% to $1.5 billion in 2024, then jumped by 42.29% to $2.1 billion in 2025, then grew by 0.09% to $2.1 billion in 2026.
• Business Quant data shows HALO's Total Debt at $2.1 billion in Q1 2026, $2.1 billion in Q4 2025, and $1.5 billion in Q3 2025.